反応式
CCOC(=O)c1cc2cccc(Br)c2o1.c1ccc(CCN2CCNCC2)nc1>C1COCCO1.CC(C)c1cc(C(C)C)c(-c2ccccc2P(C2CCCCC2)C2CCCCC2)c(C(C)C)c1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C([O-])[O-].[Cs+].[Cs+].[Pd].[Pd]>CCOC(=O)c1cc2cccc(N3CCN(CCc4ccccn4)CC3)c2o1参加物
反応物 2
生成物 1
試薬・触媒・溶媒 4
反応条件
- 温度
- 95 °C
実験手順
12/01 2009 15:21:58 +0100 To ethyl 7-bromobenzofuran-2-carboxylate (0.900 g, 3.34 mmol) and 1-(2-(pyridin-2-yl)ethyl)piperazine (0.672 g, 3.51 mmol) in dry degassed dioxane (13 mL) were added Cesium carbonate (1.417 g, 4.35 mmol), 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (0.159 g, 0.33 mmol) and Tris(dibenzylideneacetone)dipalladium(0) (0.153 g, 0.17 mmol) under argon and the reaction heated at 95°C o/n. All starting material consumed. Water and DCM were added and the layers separated. The aq phase was extracted with DCM (3x). The combined org phases were washed with water, dried (MgSO4), filtered and evaporated. The crude was purified by flash chrom. (SiO2; DCM/MeOH 95/5) to give EN02198-25-001: 47.3 mg (fraction 12 from the flash) of the product as a pale yellow solid. This batch was submitted to test. EN02198-25-002: 0.460 g (fractions 11 and 13-18 from the flash) of the product as a pale brown solid.
出典と根拠
- ORDレコード
- ord-61dd76cabf5f48cb8028fe718c7f9d72
- 出典データセット
- 750 AstraZeneca ELN dataset
- 元リンク
- 出典を表示
関連ノート
読み込み中…